Scholarlink

<p>Carvedilol (CVL) is a lipophilic third generation non-selective beta and alpha-1 adrenoceptor blocker. CVL has pleiotropic antioxidant and anti-inflammatory effects by reducing the production of reactive oxygen species (ROS) and inhibiting of inflammatory signaling pathways. In virtue of its antioxidant and anti-inflammatory effects, CVL can ameliorate COVID-19 and related complications. Therefore, the aim of the present review was to illustrate the potential role of CVL in the management of COVID-19. CVL has anti-SARS-CoV-2 activity by inhibiting 3-CLpro, which is involved in the replication of this virus. CVL inhibits the release of pro-inflammatory cytokines, improves anti-inflammatory cytokines, inhibit <i>β</i>/<i>α</i>adrenoceptors-mediated immune activation, and suppression of sympathetic over-activity. Thus, CVL may prevent the association between sympathetic and cytokine storms in COVID-19. These verdicts suggest that CVL through its antioxidant, anti-inflammatory, and blocking of <i>β</i>/<i>α</i>adrenoceptors, might be a possible candidate against COVID-19-induced inflammatory changes, oxidative stress, and the development of dysautonomia. In conclusion, CVL could be a possible drug in the management of COVID-19 by attenuating the development of cytokine and sympathetic storms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The potential role of carvedilol in COVID-19 management: perspective and take-away

  • 期刊论文

  • 发表日期：

    2025年8月27日

查看全文
  • Hayder M. Al-Kuraishy,
  • Maii A. Abdelnaby,
  • Marios Papadakis,
  • Athanasios Alexiou,
  • Gaber El-Saber Batiha

摘要

Carvedilol (CVL) is a lipophilic third generation non-selective beta and alpha-1 adrenoceptor blocker. CVL has pleiotropic antioxidant and anti-inflammatory effects by reducing the production of reactive oxygen species (ROS) and inhibiting of inflammatory signaling pathways. In virtue of its antioxidant and anti-inflammatory effects, CVL can ameliorate COVID-19 and related complications. Therefore, the aim of the present review was to illustrate the potential role of CVL in the management of COVID-19. CVL has anti-SARS-CoV-2 activity by inhibiting 3-CLpro, which is involved in the replication of this virus. CVL inhibits the release of pro-inflammatory cytokines, improves anti-inflammatory cytokines, inhibit β/αadrenoceptors-mediated immune activation, and suppression of sympathetic over-activity. Thus, CVL may prevent the association between sympathetic and cytokine storms in COVID-19. These verdicts suggest that CVL through its antioxidant, anti-inflammatory, and blocking of β/αadrenoceptors, might be a possible candidate against COVID-19-induced inflammatory changes, oxidative stress, and the development of dysautonomia. In conclusion, CVL could be a possible drug in the management of COVID-19 by attenuating the development of cytokine and sympathetic storms.